Prostate Cancer Old Problems and New Approaches - Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects

Kenneth V. Honn, Amer Aref, Yong Q. Chen, Miehael L. Cher, John D. Crissman, Jeffrey D. Forman, Xiang Gao, David Grignon, Maha Hussain, Arthur T. Porter, J. Edson Pontes, Isaae Powell, Bruce Redman, Wael Sakr, Richard Severson, Dean G. Tang, David P. Wood

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Diagnostic and prognostic markers for prostatic cancer (PCa) include conventional protein markers (e.g., PAP, PSA, PSMA, PIP, OA-519, Ki-67, PCNA, TF, collagenase, and TIMP 1), angiogenesis indicator (e.g., factor VIII), neuroendocrine differentiation status, adhesion molecules (E-cadherin, integrin), bone matrix degrading products (e.g., ICPT), as well as molecular markers (e.g., PSA, PSMA, p53, 12LOX, and MSI). Currently, only PSA is used clinically for early diagnosis and monitoring of PCa. The histological differential diagnosis of prostatic adenocarcinoma includes normal tissues such as Cowper's gland, Paraganglion tissue and seminal vesicle or ejaculatory duct as well as pathological conditions such as atypical adenomatous hyperplasia, atrophy, basal cell hyperplasia and sclerosing adenosis. A common PCa is characterized by a remarkable heterogeneity in terms of its differentiation, microscopic growth patterns and biological aggressiveness. Most PCa are multifocal with signi ficant variations in tumor grade between anatomically separated tumor foci. The Gleason grading system which recognizes five major grades defined by patterns of neoplastic growth has gained almost uniform acceptance. In predicting the biologic behavior of PCa clinical and pathological stages are used as the major prognostic indicators. Among the cell proliferation and death regulators androgens are critical survival factors for normal prostate epithelial cells as well as for the androgen-dependent human prostatic cancer cells. The androgen ablation has been shown to increase the apoptotic index in prostatic cancer patients and castration also promotes apoptotic death of human prostate carcinoma grown in mice. The progression of PCa, similarly to other malignancies, is a multistep process, accompanied by genetic and epigenetic changes, involving phenomenons as adhesion, invasion and angiogenesis (without prostate specific features).

Original languageEnglish (US)
Pages (from-to)191-211
Number of pages21
JournalPathology & Oncology Research
Volume2
Issue number3
DOIs
StatePublished - Sep 1996
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Biomarkers
Pathology
Androgens
Prostate
Hyperplasia
Bulbourethral Glands
Ejaculatory Ducts
Genetic Epigenesis
Genetic Phenomena
Neoplasms
Bone Matrix
Tissue Inhibitor of Metalloproteinase-1
Neoplasm Grading
Seminal Vesicles
Castration
Factor VIII
Proliferating Cell Nuclear Antigen
Cadherins
Growth

Keywords

  • biology
  • diagnosis
  • pathology
  • prognosis
  • prostate cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Prostate Cancer Old Problems and New Approaches - Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects. / Honn, Kenneth V.; Aref, Amer; Chen, Yong Q.; Cher, Miehael L.; Crissman, John D.; Forman, Jeffrey D.; Gao, Xiang; Grignon, David; Hussain, Maha; Porter, Arthur T.; Pontes, J. Edson; Powell, Isaae; Redman, Bruce; Sakr, Wael; Severson, Richard; Tang, Dean G.; Wood, David P.

In: Pathology & Oncology Research, Vol. 2, No. 3, 09.1996, p. 191-211.

Research output: Contribution to journalArticle

Honn, KV, Aref, A, Chen, YQ, Cher, ML, Crissman, JD, Forman, JD, Gao, X, Grignon, D, Hussain, M, Porter, AT, Pontes, JE, Powell, I, Redman, B, Sakr, W, Severson, R, Tang, DG & Wood, DP 1996, 'Prostate Cancer Old Problems and New Approaches - Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects', Pathology & Oncology Research, vol. 2, no. 3, pp. 191-211. https://doi.org/10.1007/BF02903527
Honn, Kenneth V. ; Aref, Amer ; Chen, Yong Q. ; Cher, Miehael L. ; Crissman, John D. ; Forman, Jeffrey D. ; Gao, Xiang ; Grignon, David ; Hussain, Maha ; Porter, Arthur T. ; Pontes, J. Edson ; Powell, Isaae ; Redman, Bruce ; Sakr, Wael ; Severson, Richard ; Tang, Dean G. ; Wood, David P. / Prostate Cancer Old Problems and New Approaches - Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects. In: Pathology & Oncology Research. 1996 ; Vol. 2, No. 3. pp. 191-211.
@article{205ebafe4aa440d980c98f23064ec678,
title = "Prostate Cancer Old Problems and New Approaches - Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects",
abstract = "Diagnostic and prognostic markers for prostatic cancer (PCa) include conventional protein markers (e.g., PAP, PSA, PSMA, PIP, OA-519, Ki-67, PCNA, TF, collagenase, and TIMP 1), angiogenesis indicator (e.g., factor VIII), neuroendocrine differentiation status, adhesion molecules (E-cadherin, integrin), bone matrix degrading products (e.g., ICPT), as well as molecular markers (e.g., PSA, PSMA, p53, 12LOX, and MSI). Currently, only PSA is used clinically for early diagnosis and monitoring of PCa. The histological differential diagnosis of prostatic adenocarcinoma includes normal tissues such as Cowper's gland, Paraganglion tissue and seminal vesicle or ejaculatory duct as well as pathological conditions such as atypical adenomatous hyperplasia, atrophy, basal cell hyperplasia and sclerosing adenosis. A common PCa is characterized by a remarkable heterogeneity in terms of its differentiation, microscopic growth patterns and biological aggressiveness. Most PCa are multifocal with signi ficant variations in tumor grade between anatomically separated tumor foci. The Gleason grading system which recognizes five major grades defined by patterns of neoplastic growth has gained almost uniform acceptance. In predicting the biologic behavior of PCa clinical and pathological stages are used as the major prognostic indicators. Among the cell proliferation and death regulators androgens are critical survival factors for normal prostate epithelial cells as well as for the androgen-dependent human prostatic cancer cells. The androgen ablation has been shown to increase the apoptotic index in prostatic cancer patients and castration also promotes apoptotic death of human prostate carcinoma grown in mice. The progression of PCa, similarly to other malignancies, is a multistep process, accompanied by genetic and epigenetic changes, involving phenomenons as adhesion, invasion and angiogenesis (without prostate specific features).",
keywords = "biology, diagnosis, pathology, prognosis, prostate cancer",
author = "Honn, {Kenneth V.} and Amer Aref and Chen, {Yong Q.} and Cher, {Miehael L.} and Crissman, {John D.} and Forman, {Jeffrey D.} and Xiang Gao and David Grignon and Maha Hussain and Porter, {Arthur T.} and Pontes, {J. Edson} and Isaae Powell and Bruce Redman and Wael Sakr and Richard Severson and Tang, {Dean G.} and Wood, {David P.}",
year = "1996",
month = "9",
doi = "10.1007/BF02903527",
language = "English (US)",
volume = "2",
pages = "191--211",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Prostate Cancer Old Problems and New Approaches - Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects

AU - Honn, Kenneth V.

AU - Aref, Amer

AU - Chen, Yong Q.

AU - Cher, Miehael L.

AU - Crissman, John D.

AU - Forman, Jeffrey D.

AU - Gao, Xiang

AU - Grignon, David

AU - Hussain, Maha

AU - Porter, Arthur T.

AU - Pontes, J. Edson

AU - Powell, Isaae

AU - Redman, Bruce

AU - Sakr, Wael

AU - Severson, Richard

AU - Tang, Dean G.

AU - Wood, David P.

PY - 1996/9

Y1 - 1996/9

N2 - Diagnostic and prognostic markers for prostatic cancer (PCa) include conventional protein markers (e.g., PAP, PSA, PSMA, PIP, OA-519, Ki-67, PCNA, TF, collagenase, and TIMP 1), angiogenesis indicator (e.g., factor VIII), neuroendocrine differentiation status, adhesion molecules (E-cadherin, integrin), bone matrix degrading products (e.g., ICPT), as well as molecular markers (e.g., PSA, PSMA, p53, 12LOX, and MSI). Currently, only PSA is used clinically for early diagnosis and monitoring of PCa. The histological differential diagnosis of prostatic adenocarcinoma includes normal tissues such as Cowper's gland, Paraganglion tissue and seminal vesicle or ejaculatory duct as well as pathological conditions such as atypical adenomatous hyperplasia, atrophy, basal cell hyperplasia and sclerosing adenosis. A common PCa is characterized by a remarkable heterogeneity in terms of its differentiation, microscopic growth patterns and biological aggressiveness. Most PCa are multifocal with signi ficant variations in tumor grade between anatomically separated tumor foci. The Gleason grading system which recognizes five major grades defined by patterns of neoplastic growth has gained almost uniform acceptance. In predicting the biologic behavior of PCa clinical and pathological stages are used as the major prognostic indicators. Among the cell proliferation and death regulators androgens are critical survival factors for normal prostate epithelial cells as well as for the androgen-dependent human prostatic cancer cells. The androgen ablation has been shown to increase the apoptotic index in prostatic cancer patients and castration also promotes apoptotic death of human prostate carcinoma grown in mice. The progression of PCa, similarly to other malignancies, is a multistep process, accompanied by genetic and epigenetic changes, involving phenomenons as adhesion, invasion and angiogenesis (without prostate specific features).

AB - Diagnostic and prognostic markers for prostatic cancer (PCa) include conventional protein markers (e.g., PAP, PSA, PSMA, PIP, OA-519, Ki-67, PCNA, TF, collagenase, and TIMP 1), angiogenesis indicator (e.g., factor VIII), neuroendocrine differentiation status, adhesion molecules (E-cadherin, integrin), bone matrix degrading products (e.g., ICPT), as well as molecular markers (e.g., PSA, PSMA, p53, 12LOX, and MSI). Currently, only PSA is used clinically for early diagnosis and monitoring of PCa. The histological differential diagnosis of prostatic adenocarcinoma includes normal tissues such as Cowper's gland, Paraganglion tissue and seminal vesicle or ejaculatory duct as well as pathological conditions such as atypical adenomatous hyperplasia, atrophy, basal cell hyperplasia and sclerosing adenosis. A common PCa is characterized by a remarkable heterogeneity in terms of its differentiation, microscopic growth patterns and biological aggressiveness. Most PCa are multifocal with signi ficant variations in tumor grade between anatomically separated tumor foci. The Gleason grading system which recognizes five major grades defined by patterns of neoplastic growth has gained almost uniform acceptance. In predicting the biologic behavior of PCa clinical and pathological stages are used as the major prognostic indicators. Among the cell proliferation and death regulators androgens are critical survival factors for normal prostate epithelial cells as well as for the androgen-dependent human prostatic cancer cells. The androgen ablation has been shown to increase the apoptotic index in prostatic cancer patients and castration also promotes apoptotic death of human prostate carcinoma grown in mice. The progression of PCa, similarly to other malignancies, is a multistep process, accompanied by genetic and epigenetic changes, involving phenomenons as adhesion, invasion and angiogenesis (without prostate specific features).

KW - biology

KW - diagnosis

KW - pathology

KW - prognosis

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0010517023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0010517023&partnerID=8YFLogxK

U2 - 10.1007/BF02903527

DO - 10.1007/BF02903527

M3 - Article

AN - SCOPUS:0010517023

VL - 2

SP - 191

EP - 211

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -